Wire · opportunities
Everlywell Brings Clairity's FDA-Authorized AI Breast Cancer Risk Assessment to Women Nationwide
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 1 October 2026 · Fusion42 review
Everlywell has launched Clairity Breast, the first FDA-authorized AI-driven software to assess five-year breast cancer risk from routine mammograms, now available nationwide through its consumer platform. This expands access to advanced predictive breast cancer risk insights, supported by updated NCCN guidelines endorsing AI-based risk assessment beginning at age 35.
This Wire brief sits within Fusion42's coverage of Digital Health.
◆ ◆ The Wire takeaway
You can now offer FDA-authorized AI breast cancer risk assessment directly to women nationwide through Everlywell, opening a rare market for consumer-access AI diagnostics. If you build digital health tools for cancer risk, integration with Everlywell’s platform could accelerate product reach faster than traditional health systems.
◆ Coverage
1 source · 1 Oct 2026
◆ Related on Wire
◆ Topics